desipramine has been researched along with Apoplexy in 1 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Redondo, M | 1 |
| Zarruk, JG | 1 |
| Ceballos, P | 1 |
| Pérez, DI | 1 |
| Pérez, C | 1 |
| Perez-Castillo, A | 1 |
| Moro, MA | 1 |
| Brea, J | 1 |
| Val, C | 1 |
| Cadavid, MI | 1 |
| Loza, MI | 1 |
| Campillo, NE | 1 |
| Martínez, A | 1 |
| Gil, C | 1 |
1 other study available for desipramine and Apoplexy
| Article | Year |
|---|---|
Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.
Topics: Animals; Blood-Brain Barrier; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 7; Disease | 2012 |